{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:25:45Z","timestamp":1794245145311,"version":"4.9.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA238268"],"award-info":[{"award-number":["R01CA238268"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K99CA303346"],"award-info":[{"award-number":["K99CA303346"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DRG-2529-24"],"award-info":[{"award-number":["DRG-2529-24"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment but its efficacy remains limited in solid tumors due to antigen heterogeneity, an immunosuppressive microenvironment, and the glycocalyx barrier. The glycocalyx, composed of dense glycoproteins such as MUC1, is markedly expanded in cancers, where it impedes immune cell access and antigen engagement, thereby reducing efficacy. In most adenocarcinomas, Tn antigen, comprising N-acetylgalactosamine linked to serine or threonine, is overexpressed. Tn-MUC1, a truncated form of MUC1 decorated with Tn antigen, is frequently overexpressed in pancreatic cancer. Here, we incorporate a non-signaling glyco-bridge binder recognizing Tn-MUC1 into mesothelin-directed CAR-T cells. This bridge enhances tumor recognition and cytotoxicity by increasing avidity and facilitating CAR activation in a density- and affinity-dependent manner. To broaden its applicability, we design a tandem Helix pomatia agglutinin (HPA) lectin-based bridge that recognizes Tn antigens across cancer types. CAR-T cells with the HPA-bridge exhibit superior cytotoxicity in pancreatic cancer models.<\/jats:p>","DOI":"10.1038\/s41467-025-66102-2","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:14:23Z","timestamp":1765379663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-3114","authenticated-orcid":false,"given":"Sangwoo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy E.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli P.","family":"Darnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7388-7736","authenticated-orcid":false,"given":"Hana","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-233X","authenticated-orcid":false,"given":"Filippo","family":"Birocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Bouffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Salas-Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9177-0251","authenticated-orcid":false,"given":"Giulia","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-0221","authenticated-orcid":false,"given":"Mark B.","family":"Leick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"66102_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"66102_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"66102_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"66102_CR4","first-page":"669","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard, A. FDA approves first CAR T therapy. Nat. Rev. Drug Discov. 16, 669 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66102_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"66102_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-20-0405","volume":"9","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol. Res. 9, 707\u2013722 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"66102_CR7","doi-asserted-by":"publisher","first-page":"e000676","DOI":"10.1136\/jitc-2020-000676","volume":"8","author":"T St\u00fcber","year":"2020","unstructured":"St\u00fcber, T. et al. Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J. Immunother. Cancer 8, e000676 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"66102_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn9857","volume":"10","author":"P Erler","year":"2024","unstructured":"Erler, P. et al. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Sci. Adv. 10, eadn9857 (2024).","journal-title":"Sci. Adv."},{"key":"66102_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","volume":"68","author":"D Raj","year":"2019","unstructured":"Raj, D. et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut 68, 1052\u20131064 (2019).","journal-title":"Gut"},{"key":"66102_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37616-4","volume":"14","author":"N Li","year":"2023","unstructured":"Li, N. et al. The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nat. Commun. 14, 1986 (2023).","journal-title":"Nat. Commun."},{"key":"66102_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101803","volume":"39","author":"Y Yuan","year":"2024","unstructured":"Yuan, Y. et al. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. Transl. Oncol. 39, 101803 (2024).","journal-title":"Transl. Oncol."},{"key":"66102_CR12","doi-asserted-by":"publisher","unstructured":"Ghasempour, S. & Freeman, S. A. The glycocalyx and immune evasion in cancer. FEBS J. https:\/\/doi.org\/10.1111\/febs.16236 (2021).","DOI":"10.1111\/febs.16236"},{"key":"66102_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D \u00d6hlund","year":"2014","unstructured":"\u00d6hlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503\u20131523 (2014).","journal-title":"J. Exp. Med."},{"key":"66102_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","volume":"22","author":"AA Connor","year":"2022","unstructured":"Connor, A. A. & Gallinger, S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat. Rev. Cancer 22, 131\u2013142 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"66102_CR15","first-page":"69","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L. & Kenderian, S. S. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol. Ther. 25, 69\u201377 (2022).","journal-title":"Mol. Ther."},{"key":"66102_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/ni.3552","volume":"17","author":"R Beatson","year":"2016","unstructured":"Beatson, R. et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat. Immunol. 17, 1273\u20131281 (2016).","journal-title":"Nat. Immunol."},{"key":"66102_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41563-024-01808-0","volume":"23","author":"S Park","year":"2024","unstructured":"Park, S. et al. Immunoengineering can overcome the glycocalyx armour of cancer cells. Nat. Mater. 23, 429\u2013438 (2024).","journal-title":"Nat. Mater."},{"key":"66102_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-11","volume":"9","author":"JAA Gubbels","year":"2010","unstructured":"Gubbels, J. A. A. et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 9, 11 (2010).","journal-title":"Mol. Cancer"},{"key":"66102_CR19","doi-asserted-by":"publisher","unstructured":"Pedram, K. et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01840-6 (2023).","DOI":"10.1038\/s41587-023-01840-6"},{"key":"66102_CR20","doi-asserted-by":"publisher","unstructured":"Park, S. et al. Leucine zipper-based SAIM imaging identifies therapeutic agents to disrupt the cancer cell glycocalyx for enhanced immunotherapy. Preprint at https:\/\/doi.org\/10.1101\/2024.12.05.627089 (2024).","DOI":"10.1101\/2024.12.05.627089"},{"key":"66102_CR21","doi-asserted-by":"publisher","unstructured":"Park, S. et al. Collagen mineralization decreases NK cell-mediated cytotoxicity of breast cancer cells via increased glycocalyx thickness. Adv. Mater. 2311505 https:\/\/doi.org\/10.1002\/adma.202311505 (2024).","DOI":"10.1002\/adma.202311505"},{"key":"66102_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178804","volume":"9","author":"EE Hollander","year":"2024","unstructured":"Hollander, E. E. et al. N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance. JCI Insight 9, e178804 (2024).","journal-title":"JCI Insight"},{"key":"66102_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey","year":"2016","unstructured":"Posey, A. D. et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44, 1444\u20131454 (2016).","journal-title":"Immunity"},{"key":"66102_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85747-9","volume":"11","author":"K Supimon","year":"2021","unstructured":"Supimon, K. et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci. Rep. 11, 6276 (2021).","journal-title":"Sci. Rep."},{"key":"66102_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/cam4.2733","volume":"9","author":"Z Mei","year":"2020","unstructured":"Mei, Z. et al. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med. 9, 640\u2013652 (2020).","journal-title":"Cancer Med."},{"key":"66102_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","volume":"10","author":"R Zhou","year":"2019","unstructured":"Zhou, R. et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front. Immunol. 10, 1149 (2019).","journal-title":"Front. Immunol."},{"key":"66102_CR27","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cells8091070","volume":"8","author":"M Yazdanifar","year":"2019","unstructured":"Yazdanifar, M. et al. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells 8, 1070 (2019).","journal-title":"Cells"},{"key":"66102_CR28","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901\u20134909 (2008).","journal-title":"J. Immunol."},{"key":"66102_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2559.2010.03667.x","volume":"57","author":"CHMJ Van Elssen","year":"2010","unstructured":"Van Elssen, C. H. M. J. et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57, 597\u2013606 (2010).","journal-title":"Histopathology"},{"key":"66102_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2141.2006.06331.x","volume":"135","author":"S Cloosen","year":"2006","unstructured":"Cloosen, S. et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br. J. Haematol. 135, 513\u2013516 (2006).","journal-title":"Br. J. Haematol."},{"key":"66102_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/his.12330","volume":"64","author":"M Andrulis","year":"2014","unstructured":"Andrulis, M. et al. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization. Histopathology 64, 799\u2013806 (2014).","journal-title":"Histopathology"},{"key":"66102_CR32","doi-asserted-by":"publisher","first-page":"e14513","DOI":"10.1200\/JCO.2021.39.15_suppl.e14513","volume":"39","author":"R Gutierrez","year":"2021","unstructured":"Gutierrez, R. et al. Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. JCO 39, e14513\u2013e14513 (2021).","journal-title":"JCO"},{"key":"66102_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3072","volume":"14","author":"B Greco","year":"2022","unstructured":"Greco, B. et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci. Transl. Med. 14, eabg3072 (2022).","journal-title":"Sci. Transl. Med."},{"key":"66102_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev-immunol-101819-074237","volume":"39","author":"JY Zhou","year":"2021","unstructured":"Zhou, J. Y. & Cobb, B. A. Glycans in immunologic health and disease. Annu. Rev. Immunol. 39, 511\u2013536 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"66102_CR35","doi-asserted-by":"publisher","first-page":"e0141253","DOI":"10.1371\/journal.pone.0141253","volume":"10","author":"C Costa","year":"2015","unstructured":"Costa, C. et al. Abnormal protein glycosylation and activated PI3K\/Akt\/mTOR pathway: role in bladder cancer prognosis and targeted therapeutics. PLoS ONE 10, e0141253 (2015).","journal-title":"PLoS ONE"},{"key":"66102_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1053\/hupa.2000.9776","volume":"31","author":"B Davidson","year":"2000","unstructured":"Davidson, B. et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 31, 1081\u20131087 (2000).","journal-title":"Hum. Pathol."},{"key":"66102_CR37","first-page":"335","volume":"54","author":"GF Springer","year":"1975","unstructured":"Springer, G. F., Desai, P. R. & Banatwala, I. Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J. Natl. Cancer Inst. 54, 335\u2013339 (1975).","journal-title":"J. Natl. Cancer Inst."},{"key":"66102_CR38","first-page":"295","volume":"4","author":"S Zhang","year":"1998","unstructured":"Zhang, S. et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4, 295\u2013302 (1998).","journal-title":"Clin. Cancer Res."},{"key":"66102_CR39","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-12-2662","volume":"19","author":"N Remmers","year":"2013","unstructured":"Remmers, N. et al. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin. Cancer Res. 19, 1981\u20131993 (2013).","journal-title":"Clin. Cancer Res."},{"key":"66102_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF01366970","volume":"121","author":"G Ohshio","year":"1995","unstructured":"Ohshio, G. et al. Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody (MLS128) in normal and malignant tissues of the digestive tract. J. Cancer Res. Clin. Oncol. 121, 247\u2013252 (1995).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"66102_CR41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1309\/LWP3-MFA8-8KX7-60YQ","volume":"118","author":"A L\u00f3pez-Ferrer","year":"2002","unstructured":"L\u00f3pez-Ferrer, A., Barranco, C. & de Bol\u00f3s, C. Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma. Am. J. Clin. Pathol. 118, 749\u2013755 (2002).","journal-title":"Am. J. Clin. Pathol."},{"key":"66102_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4708-8","volume":"18","author":"X Sun","year":"2018","unstructured":"Sun, X., Ju, T. & Cummings, R. D. Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers. BMC Cancer 18, 827 (2018).","journal-title":"BMC Cancer"},{"key":"66102_CR43","doi-asserted-by":"publisher","first-page":"16613","DOI":"10.1073\/pnas.262438199","volume":"99","author":"T Ju","year":"2002","unstructured":"Ju, T. & Cummings, R. D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc. Natl. Acad. Sci. USA 99, 16613\u201316618 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66102_CR44","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-07-2345","volume":"68","author":"T Ju","year":"2008","unstructured":"Ju, T. et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 68, 1636\u20131646 (2008).","journal-title":"Cancer Res."},{"key":"66102_CR45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.1129200","volume":"314","author":"A Schietinger","year":"2006","unstructured":"Schietinger, A. et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314, 304\u2013308 (2006).","journal-title":"Science"},{"key":"66102_CR46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/4371252a","volume":"437","author":"T Ju","year":"2005","unstructured":"Ju, T. & Cummings, R. D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437, 1252 (2005).","journal-title":"Nature"},{"key":"66102_CR47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3892\/ijo.2016.3638","volume":"49","author":"K Nogimori","year":"2016","unstructured":"Nogimori, K. et al. Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis. Int. J. Oncol. 49, 1369\u20131376 (2016).","journal-title":"Int. J. Oncol."},{"key":"66102_CR48","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.18632\/oncotarget.3117","volume":"6","author":"M-J Huang","year":"2015","unstructured":"Huang, M.-J. et al. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling. Oncotarget 6, 5650\u20135665 (2015).","journal-title":"Oncotarget"},{"key":"66102_CR49","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1158\/0008-5472.CAN-09-3911","volume":"70","author":"J-H Park","year":"2010","unstructured":"Park, J.-H. et al. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70, 2759\u20132769 (2010).","journal-title":"Cancer Res."},{"key":"66102_CR50","doi-asserted-by":"publisher","first-page":"544","DOI":"10.18632\/oncotarget.1652","volume":"5","author":"Z-Q Wang","year":"2014","unstructured":"Wang, Z.-Q. et al. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget 5, 544\u2013560 (2014).","journal-title":"Oncotarget"},{"key":"66102_CR51","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1038\/onc.2011.194","volume":"30","author":"K Taniuchi","year":"2011","unstructured":"Taniuchi, K. et al. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene 30, 4843\u20134854 (2011).","journal-title":"Oncogene"},{"key":"66102_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/CBM-130375","volume":"14","author":"T Ju","year":"2014","unstructured":"Ju, T., Aryal, R. P., Kudelka, M. R., Wang, Y. & Cummings, R. D. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 14, 63\u201381 (2014).","journal-title":"Cancer Biomark."},{"key":"66102_CR53","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/(SICI)1097-0215(20000615)86:6<753::AID-IJC1>3.0.CO;2-#","volume":"86","author":"A Babino","year":"2000","unstructured":"Babino, A. et al. Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis. Int. J. Cancer 86, 753\u2013759 (2000).","journal-title":"Int. J. Cancer"},{"key":"66102_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/sj.pcan.4500762","volume":"8","author":"JC O\u2019Connor","year":"2005","unstructured":"O\u2019Connor, J. C., Julian, J., Lim, S. D. & Carson, D. D. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis. 8, 36\u201344 (2005).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"66102_CR55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1023\/A:1006345301364","volume":"58","author":"MD Walsh","year":"1999","unstructured":"Walsh, M. D., Luckie, S. M., Cummings, M. C., Antalis, T. M. & McGuckin, M. A. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res. Treat. 58, 255\u2013266 (1999).","journal-title":"Breast Cancer Res. Treat."},{"key":"66102_CR56","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904\u2013918 (2021).","journal-title":"Nat. Cancer"},{"key":"66102_CR57","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41, 1871\u20131891.e6 (2023).","journal-title":"Cancer Cell"},{"key":"66102_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou, A. et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci. Transl. Med. 13, eabh1962 (2021).","journal-title":"Sci. Transl. Med."},{"key":"66102_CR59","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-06-0441","volume":"12","author":"R Hassan","year":"2006","unstructured":"Hassan, R. et al. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin. Cancer Res. 12, 4983\u20134988 (2006).","journal-title":"Clin. Cancer Res."},{"key":"66102_CR60","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack, M., Riethm\u00fcller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 92, 7021\u20137025 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66102_CR61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","volume":"9","author":"JC Boucher","year":"2021","unstructured":"Boucher, J. C. et al. CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunol. Res. 9, 62\u201374 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"66102_CR62","doi-asserted-by":"publisher","first-page":"113616","DOI":"10.1016\/j.biopha.2022.113616","volume":"154","author":"C-L Li","year":"2022","unstructured":"Li, C.-L. et al. Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy. Biomed. Pharmacother. 154, 113616 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"66102_CR63","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1093\/clinids\/9.Supplement_1.S43","volume":"9","author":"H Van Cauteren","year":"1987","unstructured":"Van Cauteren, H., Heykants, J., De Coster, R. & Cauwenbergh, G. Itraconazole: pharmacologic studies in animals and humans. Rev. Infect. Dis. 9, S43\u2013S46 (1987).","journal-title":"Rev. Infect. Dis."},{"key":"66102_CR64","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1086\/605499","volume":"49","author":"JM Lestner","year":"2009","unstructured":"Lestner, J. M. et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin. Infect. Dis. 49, 928\u2013930 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"66102_CR65","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1078-0432.CCR-15-1888","volume":"22","author":"JS Shim","year":"2016","unstructured":"Shim, J. S. et al. Divergence of antiangiogenic activity and hepatotoxicity of different stereoisomers of itraconazole. Clin. Cancer Res. 22, 2709\u20132720 (2016).","journal-title":"Clin. Cancer Res."},{"key":"66102_CR66","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","volume":"305","author":"A W\u00f6rn","year":"2001","unstructured":"W\u00f6rn, A. & Pl\u00fcckthun, A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305, 989\u20131010 (2001).","journal-title":"J. Mol. Biol."},{"key":"66102_CR67","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jmb.2005.01.053","volume":"347","author":"D R\u00f6thlisberger","year":"2005","unstructured":"R\u00f6thlisberger, D., Honegger, A. & Pl\u00fcckthun, A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 347, 773\u2013789 (2005).","journal-title":"J. Mol. Biol."},{"key":"66102_CR68","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"66102_CR69","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","volume":"31","author":"D Sommermeyer","year":"2017","unstructured":"Sommermeyer, D. et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 31, 2191\u20132199 (2017).","journal-title":"Leukemia"},{"key":"66102_CR70","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"66102_CR71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10719-012-9437-7","volume":"30","author":"K Lavrsen","year":"2013","unstructured":"Lavrsen, K. et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj. J. 30, 227\u2013236 (2013).","journal-title":"Glycoconj. J."},{"key":"66102_CR72","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.1039\/D0CC06349E","volume":"56","author":"J Mac\u00edas-Le\u00f3n","year":"2020","unstructured":"Mac\u00edas-Le\u00f3n, J. et al. Structural characterization of an unprecedented lectin-like antitumoral anti-MUC1 antibody. Chem. Commun. 56, 15137\u201315140 (2020).","journal-title":"Chem. Commun."},{"key":"66102_CR73","doi-asserted-by":"publisher","first-page":"10279","DOI":"10.1111\/jcmm.15684","volume":"24","author":"S Wang","year":"2020","unstructured":"Wang, S., You, L., Dai, M. & Zhao, Y. Mucins in pancreatic cancer: a well-established but promising family for diagnosis, prognosis and therapy. J. Cell Mol. Med. 24, 10279\u201310289 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"66102_CR74","doi-asserted-by":"publisher","first-page":"20171","DOI":"10.1074\/jbc.M603452200","volume":"281","author":"J-F Sanchez","year":"2006","unstructured":"Sanchez, J.-F. et al. Biochemical and structural analysis of Helix pomatia agglutinin. A hexameric lectin with a novel fold. J. Biol. Chem. 281, 20171\u201320180 (2006).","journal-title":"J. Biol. Chem."},{"key":"66102_CR75","doi-asserted-by":"publisher","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","volume":"111","author":"P Radhakrishnan","year":"2014","unstructured":"Radhakrishnan, P. et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc. Natl. Acad. Sci. USA 111, E4066\u2013E4075 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66102_CR76","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/0016-5085(91)90671-7","volume":"100","author":"S Itzkowitz","year":"1991","unstructured":"Itzkowitz, S. et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 100, 1691\u20131700 (1991).","journal-title":"Gastroenterology"},{"key":"66102_CR77","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/1097-0142(19890815)64:4<834::AID-CNCR2820640413>3.0.CO;2-A","volume":"64","author":"N Barr","year":"1989","unstructured":"Barr, N., Taylor, C. R., Young, T. & Springer, G. F. Are pancarcinoma T and Tn differentiation antigens? Cancer 64, 834\u2013841 (1989).","journal-title":"Cancer"},{"key":"66102_CR78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1021\/acs.molpharmaceut.1c00744","volume":"19","author":"F Bulteau","year":"2022","unstructured":"Bulteau, F. et al. Targeting Tn-antigen-positive human tumors with a recombinant human macrophage galactose C-type lectin. Mol. Pharm. 19, 235\u2013245 (2022).","journal-title":"Mol. Pharm."},{"key":"66102_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39119-8","volume":"14","author":"MP Lenza","year":"2023","unstructured":"Lenza, M. P. et al. Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b. Nat. Commun. 14, 3496 (2023).","journal-title":"Nat. Commun."},{"key":"66102_CR80","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s43018-024-00744-x","volume":"5","author":"A Dobrin","year":"2024","unstructured":"Dobrin, A. et al. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies. Nat. Cancer 5, 760\u2013773 (2024).","journal-title":"Nat. Cancer"},{"key":"66102_CR81","doi-asserted-by":"publisher","first-page":"e005891","DOI":"10.1136\/jitc-2022-005891","volume":"11","author":"MK McKenna","year":"2023","unstructured":"McKenna, M. K. et al. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma. J. Immunother. Cancer 11, e005891 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"66102_CR82","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for Relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"66102_CR83","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00018-022-04524-7","volume":"79","author":"AV Mel\u00e9ndez","year":"2022","unstructured":"Mel\u00e9ndez, A. V. et al. Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells. Cell Mol. Life Sci. 79, 513 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"66102_CR84","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1073\/pnas.1813020116","volume":"116","author":"SA Malaker","year":"2019","unstructured":"Malaker, S. A. et al. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc. Natl. Acad. Sci. USA 116, 7278\u20137287 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66102_CR85","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/1097-0142(19930701)72:1<154::AID-CNCR2820720129>3.0.CO;2-C","volume":"72","author":"T Hirao","year":"1993","unstructured":"Hirao, T., Sakamoto, Y., Kamada, M., Hamada, S. & Aono, T. Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 72, 154\u2013159 (1993).","journal-title":"Cancer"},{"key":"66102_CR86","first-page":"2229","volume":"56","author":"K Terasawa","year":"1996","unstructured":"Terasawa, K., Furumoto, H., Kamada, M. & Aono, T. Expression of Tn and sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells. Cancer Res. 56, 2229\u20132232 (1996).","journal-title":"Cancer Res."},{"key":"66102_CR87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1025815113599","volume":"23","author":"JC Byrd","year":"2004","unstructured":"Byrd, J. C. & Bresalier, R. S. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 23, 77\u201399 (2004).","journal-title":"Cancer Metastasis Rev."},{"key":"66102_CR88","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/1535-7163.MCT-21-0017","volume":"20","author":"B Hagerty","year":"2021","unstructured":"Hagerty, B. et al. Novel humanized mesothelin-expressing genetically engineered mouse models underscore challenges in delivery of complex therapeutics to pancreatic cancers. Mol. Cancer Ther. 20, 2082\u20132092 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"66102_CR89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13046-016-0314-2","volume":"35","author":"E Zervos","year":"2016","unstructured":"Zervos, E., Agle, S., Freistaedter, A. G., Jones, G. J. B. & Roper, R. L. Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer. J. Exp. Clin. Cancer Res. 35, 39 (2016).","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66102-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:01:46Z","timestamp":1766149306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66102-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66102"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66102-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.V.M. and S.P. are inventors on patent applications filed by MGH related to CAR-T cell technologies described in this study. All other authors declare no competing interests. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab and Luminary) and University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in 2SeventyBio, A2Bio, Affyimmune, BendBio, Cargo, GBM newco, Model T bio, Neximmune, and Oncternal. M.V.M. receives Grant\/Research support from Kite Pharma, Moderna, and Sobi. M.V.M. has served as a consultant for multiple companies involved in cell therapies. M.V.M.\u2019s competing interests are managed by Mass General Brigham. M.B.L. is a contributor to patent filings on CAR-T technology held by the Massachusetts General Hospital and has served as a consultant for BioNtech, Cabaletta Bio, and Onclive.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11246"}}